650 related articles for article (PubMed ID: 25194424)
1. Treatment of post-menopausal osteoporosis: beyond bisphosphonates.
Ishtiaq S; Fogelman I; Hampson G
J Endocrinol Invest; 2015 Jan; 38(1):13-29. PubMed ID: 25194424
[TBL] [Abstract][Full Text] [Related]
2. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
[TBL] [Abstract][Full Text] [Related]
3. Management of postmenopausal osteoporosis and the prevention of fractures.
Gambacciani M; Levancini M
Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
[TBL] [Abstract][Full Text] [Related]
4. How to manage postmenopausal osteoporosis?
Body JJ
Acta Clin Belg; 2011; 66(6):443-7. PubMed ID: 22338309
[TBL] [Abstract][Full Text] [Related]
5. Antifracture efficacy of currently available therapies for postmenopausal osteoporosis.
Reginster JY
Drugs; 2011 Jan; 71(1):65-78. PubMed ID: 21175240
[TBL] [Abstract][Full Text] [Related]
6. Osteoporosis: now and the future.
Rachner TD; Khosla S; Hofbauer LC
Lancet; 2011 Apr; 377(9773):1276-87. PubMed ID: 21450337
[TBL] [Abstract][Full Text] [Related]
7. Developments in the pharmacotherapeutic management of osteoporosis.
Close P; Neuprez A; Reginster JY
Expert Opin Pharmacother; 2006 Aug; 7(12):1603-15. PubMed ID: 16872263
[TBL] [Abstract][Full Text] [Related]
8. Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women.
Chung YE; Lee SH; Lee SY; Kim SY; Kim HH; Mirza FS; Lee SK; Lorenzo JA; Kim GS; Koh JM
Osteoporos Int; 2012 Apr; 23(4):1235-43. PubMed ID: 21660558
[TBL] [Abstract][Full Text] [Related]
9. Bone biology, signaling pathways, and therapeutic targets for osteoporosis.
Iñiguez-Ariza NM; Clarke BL
Maturitas; 2015 Oct; 82(2):245-55. PubMed ID: 26255682
[TBL] [Abstract][Full Text] [Related]
10. Antiresorptive drugs beyond bisphosphonates and selective oestrogen receptor modulators for the management of postmenopausal osteoporosis.
Reginster JY; Neuprez A; Beaudart C; Lecart MP; Sarlet N; Bernard D; Disteche S; Bruyere O
Drugs Aging; 2014 Jun; 31(6):413-24. PubMed ID: 24797286
[TBL] [Abstract][Full Text] [Related]
11. Real-world effectiveness of osteoporosis therapies for fracture reduction in post-menopausal women.
Yusuf AA; Cummings SR; Watts NB; Feudjo MT; Sprafka JM; Zhou J; Guo H; Balasubramanian A; Cooper C
Arch Osteoporos; 2018 Mar; 13(1):33. PubMed ID: 29564735
[TBL] [Abstract][Full Text] [Related]
12. The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis.
Moshi MR; Nicolopoulos K; Stringer D; Ma N; Jenal M; Vreugdenburg T
Calcif Tissue Int; 2023 Jun; 112(6):631-646. PubMed ID: 37016189
[TBL] [Abstract][Full Text] [Related]
13. Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review.
Gallacher SJ; Dixon T
Calcif Tissue Int; 2010 Dec; 87(6):469-84. PubMed ID: 20872215
[TBL] [Abstract][Full Text] [Related]
14. Effect of osteoporosis medications on fracture healing.
Hegde V; Jo JE; Andreopoulou P; Lane JM
Osteoporos Int; 2016 Mar; 27(3):861-871. PubMed ID: 26419471
[TBL] [Abstract][Full Text] [Related]
15. Individualizing osteoporosis therapy.
Silverman S; Christiansen C
Osteoporos Int; 2012 Mar; 23(3):797-809. PubMed ID: 22218417
[TBL] [Abstract][Full Text] [Related]
16. Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis.
Lewiecki EM
J Womens Health (Larchmt); 2009 Oct; 18(10):1615-26. PubMed ID: 19857095
[TBL] [Abstract][Full Text] [Related]
17. Prevention and treatment of postmenopausal osteoporosis.
Tella SH; Gallagher JC
J Steroid Biochem Mol Biol; 2014 Jul; 142():155-70. PubMed ID: 24176761
[TBL] [Abstract][Full Text] [Related]
18. Prescription drug therapies for prevention and treatment of postmenopausal osteoporosis.
O'Connell MB
J Manag Care Pharm; 2006 Jul; 12(6 Suppl A):S10-9; quiz S26-8. PubMed ID: 17269853
[TBL] [Abstract][Full Text] [Related]
19. Osteoporosis treatment and prevention for postmenopausal women: current and future therapeutic options.
Pinkerton JV; Thomas S; Dalkin AC
Clin Obstet Gynecol; 2013 Dec; 56(4):711-21. PubMed ID: 24100598
[TBL] [Abstract][Full Text] [Related]
20. New understanding and treatments for osteoporosis.
Mazziotti G; Bilezikian J; Canalis E; Cocchi D; Giustina A
Endocrine; 2012 Feb; 41(1):58-69. PubMed ID: 22180055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
